Download 
|
< Back | |||||||||||||||||||||
| 01:54 PM | ||||||||||||||||||||||
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: UNNATTI JAIN Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: csunnattijain@gmail.com Name of the Chief Financial Officer: Ashok Somani Designation: CFO and Director EmailId: somaniashok1960@gmail.com Date: 16/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
||||||||||||||||||||||
| View all announcements for Chemo Pharma Laboratories Ltd | Source: BSE India | |||||||||||||||||||||
© 2026 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback